Samy Metyas is a Rheumatology/Immunology physician. OpenAlex indexes 10 publications with 633 citations (h-index 6).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
500 W San Bernardino Rd Ste A
Covina, CA 917223797
Telephone
626-966-1909Registry record last updated 31 Oct 2016.
Industry payments
57 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Amgen Inc.Program year2025116 payments$57,602openpaymentsdata.cms.gov ↗
- Mallinckrodt Hospital Products Inc.Program year202536 payments$34,699openpaymentsdata.cms.gov ↗
- ABBVIE INC.Program year202550 payments$31,208openpaymentsdata.cms.gov ↗
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
56.5%TNF inhibitor55.3%Certolizumab pegol65%Golimumab34%Infliximab1%Cimzia (2 Pack)0%Remicade0%Renflexis0%Enbrel Sureclick0%Humira(Cf) Pen0%Inflectra0%Simponi Aria0%Enbrel0%Humira Pen0%Part D + Part B<11 patientsFolate Analog Metabolic Inhibitor0.5%Methotrexate97%Rasuvo3%Part D<11 patients+ 14 more classes in this area
Musculoskeletal
31.1%Other drugs affecting bone structure and mineralization16%Romosozumab-aqqg99%Evenity (2 Syringes)1%Evenity0%Part D + Part B<11 patientsRANK Ligand Inhibitor13.4%Denosumab96%Prolia4%Part D + Part B≥479 patients+ 9 more classes in this area
Dermatology
8.7%Corticosteroid8.7%Methylprednisolone acetate79%Methylprednisolone sodium succinate12%Triamcinolone acetonide8%Methylprednisolone0%Methylprednisolone Sodium Succ0%Triamcinolone Acetonide0%Part D + Part B<11 patientsVitamin D Analog0%Calcipotriene100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Rheumatologic Manifestations of Post SARS-CoV-2 Infection: A Case Series
Current Rheumatology Reviews
2022 - Anakinra prevents symptoms of familial cold autoinflammatory syndrome and Raynaud's disease.
PubMed
2006 - Infliximab Treatment of Familial Mediterranean Fever and Its Effect on Secondary AA Amyloidosis
JCR Journal of Clinical Rheumatology
2004
Similar KOLs
Other experts from the same institution or the same specialty.
No other directory profiles share this institution yet.
Marc Hochberg, MD
University of Maryland School of Medicine
Michelle Petri, MD
Johns Hopkins University School of Medicine
Dinesh Khanna, MD
University of Michigan
Matthew Liang, MD
Brigham and Women's Hospital
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”